PAYX:NASDAQPaychex, Inc. Analysis
Data as of 2026-03-10 - not real-time
$98.30
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Paychex is trading around $98, well below its 30‑day support of $86.9 and substantially under its DCF‑derived fair value of $159, indicating a sizable upside potential. Valuation metrics such as a trailing P/E of 22 versus an industry average of 37 and a forward P/E of 16 reinforce the undervalued view. The company delivers a high dividend yield of 4.4% backed by strong operating cash flow and free cash flow that comfortably cover the payout, suggesting dividend sustainability. Revenue is expanding at ~18% YoY with gross margins above 73% and an impressive ROE of 40%, highlighting robust profitability and growth capacity. Recent AI‑driven enhancements to the Paycor and Paychex Flex platforms have been positively received, adding a technology‑forward narrative to the business. Technical signals are mixed: the price sits above the 20‑day SMA but below the 50‑day and 200‑day averages, the RSI is neutral at 52, while the MACD histogram is positive, hinting at short‑term bullish momentum amid a broader bearish trend. Analyst consensus remains “hold,” yet the upside estimate of roughly 19% and the strong fundamentals tilt the bias toward buying. The stock’s beta below 0.6 and stable volume suggest modest market sensitivity, though 30‑day volatility near 35% and a historical max drawdown of 45% signal notable price swings. Overall, the combination of an attractive dividend, solid growth drivers, and a clear valuation gap makes Paychex a compelling candidate for investors seeking both income and appreciation.
Given the current technical positioning near the $101 resistance level and the recent earnings beat, short‑term investors may adopt a cautious stance, while medium‑ and long‑term investors can capitalize on the undervaluation and dividend profile.
Given the current technical positioning near the $101 resistance level and the recent earnings beat, short‑term investors may adopt a cautious stance, while medium‑ and long‑term investors can capitalize on the undervaluation and dividend profile.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near short‑term resistance around $101
- Mixed technical signals (bullish MACD histogram vs bearish SMA positioning)
- Stable volume and low beta limiting rapid swings
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervaluation relative to DCF and industry multiples
- Strong earnings growth and high ROE
- AI‑driven product enhancements expanding market appeal
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustainable 4.4% dividend supported by cash flow
- Long‑term growth trajectory in payroll and HCM services
- Potential upside to fair value near $159 over multiple years
Key Metrics & Analysis
Financial Health
Revenue Growth18.30%
Profit Margin26.45%
P/E Ratio22.2
ROE40.88%
ROA11.64%
Debt/Equity129.81
P/B Ratio9.1
Op. Cash Flow$2.2B
Free Cash Flow$2.1B
Industry P/E36.8
Technical Analysis
TrendBearish
RSI52.1
Support$86.89
Resistance$101.02
MA 20$94.42
MA 50$102.44
MA 200$125.34
MACDBullish
VolumeStable
Fear & Greed Index76.91
Valuation
Fair Value$159.04
Target Price$116.93
Upside/Downside18.96%
GradeUndervalued
TypeBlend
Dividend Yield4.40%
Risk Assessment
Beta0.60
Volatility34.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.